Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $296,469.54 in Stock

Posted by Brenda Bartman on Oct 31st, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) insider Sarah Gheuens sold 7,866 shares of the stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $2,059,570.05. This represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.52, for a total transaction of $18,760.00.
On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.53, for a total value of $55,882.17.
On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Trading Down 17.9%

NASDAQ:AGIO opened at $30.55 on Friday. The stock has a market cap of $1.82 billion, a P/E ratio of -4.36 and a beta of 0.63. The stock has a 50 day simple moving average of $33.62 and a 200 day simple moving average of $31.70. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -5.81 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AGIO. Nykredit A S purchased a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $26,000. Quantinno Capital Management LP lifted its holdings in shares of Agios Pharmaceuticals by 2.7% in the first quarter. Quantinno Capital Management LP now owns 27,591 shares of the biopharmaceutical company’s stock valued at $933,000 after purchasing an additional 736 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in shares of Agios Pharmaceuticals by 6.3% during the first quarter. AlphaCentric Advisors LLC now owns 13,971 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 830 shares during the last quarter. Inspire Investing LLC boosted its position in shares of Agios Pharmaceuticals by 4.7% during the third quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock valued at $636,000 after buying an additional 861 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of Agios Pharmaceuticals by 4.0% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company’s stock valued at $960,000 after buying an additional 1,100 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AGIO shares. Bank of America raised their price target on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Royal Bank Of Canada lifted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Truist Financial lowered their target price on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a report on Wednesday, October 7th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $55.00 target price on the stock. Finally, Citigroup lifted their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Agios Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $41.50.

Get Our Latest Research Report on Agios Pharmaceuticals

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

Positive Sentiment: Agios said updated safety data showed no new cases of hepatocellular injury in sickle cell patients treated with mitapivat. The company remains confident in the drug’s benefit-risk profile, is launch-ready, and continues labeling discussions with the FDA. Agios FDA review update
Positive Sentiment: An analyst view argued that the delay may not invalidate the bullish thesis because mitapivat demonstrated meaningful reductions in transfusion burden, despite mixed efficacy on pain-crisis endpoints. Seeking Alpha upgraded the stock, while HC Wainwright maintained a “buy” rating with a $55 price target. Agios sickle cell analysis
Neutral Sentiment: Agios was expected to potentially beat estimates in its upcoming quarterly report, but the earnings preview provided no confirmed results or new operating data. Agios earnings preview
Negative Sentiment: The FDA extended the PDUFA decision date for mitapivat’s sickle cell supplemental application by three months, from November 1, 2026, to February 1, 2027. The extension followed the agency’s request for additional information on whether a Risk Evaluation and Mitigation Strategy (REMS) is needed. The FDA classified Agios’ response as a major amendment, delaying a potential approval and launch timeline. Agios shares fall on FDA review extension
Negative Sentiment: The REMS review raises concerns about possible safety-related prescribing restrictions and commercialization requirements. In addition, mitapivat did not meet the sickle-cell pain-crisis endpoint, increasing uncertainty around the breadth of its eventual label.
Negative Sentiment: A recent pre-arranged sale by Chief Medical Officer Sarah Gheuens adds a modest negative sentiment signal, although the transaction was not identified as the primary reason for the selloff. Agios insider sale

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.